top of page
INSIGHTS
We equip our clients with actionable insights drawn from meticulous analysis of data, firsthand experience, and comprehensive interviews. The contextual evidence we provide enables quick, confident decision-making. We're known for our unique ability to view opportunities and challenges from both the company's and the customer's vantage points, offering a nuanced perspective that can't be found anywhere else.
Filter
The Evolving Role of In-person vs. Digital Pharma Sales Strategies: Finding the Right Balance
Pharma’s sales model is shifting toward a strategic hybrid: balancing digital convenience with the enduring influence of in-person engagement. While digital channels offer scalable, flexible access, face-to-face interactions remain the most effective for influencing prescribing behavior. The key to success lies in tailoring the right channel to the right context: drug type, physician preference, and market dynamics all matter.
Daniel Yuan
May 28, 20254 min read
The Importance of a Harmonized KOL Engagement Strategy
A fragmented KOL engagement approach can damage credibility, strain relationships, and lead to missed insights. This article explores the value of a harmonized strategy that aligns Medical Affairs, Clinical Development, and Commercial teams to ensure consistent, strategic interactions. It also highlights the rise of Digital Opinion Leaders and the need to engage emerging voices. A coordinated approach not only builds trust with experts but also drives better outcomes and long
Federico Somaini
May 19, 20253 min read
Shortages and Slowdowns: How Pharmaceutical Tariffs Threaten Supply and Innovation
The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.
Liam Boyd
Apr 15, 20254 min read
Expanding GLP-1s: is Neurology the Next Frontier?
GLP-1 therapies transformed obesity & diabetes care and are now being explored for potential breakthroughs in neurological diseases.
Federico Somaini
Apr 2, 20255 min read
A Snapshot into AI in Drug Discovery: Progress, Hurdles, and the Path Forward
AI promised to revolutionize drug discovery, pledging faster development, reduced costs, and lowered risks. However, the reality has proven far more nuanced than initially expected. While AI is undoubtably making innovative strides in the industry, its true impact requires a closer look: where has AI succeeded, and where does it still fall short? Table of Contents The Current State of AI in Drug Discovery Current Successes Missed Marks and Growth Points A Look Ahead; Braci
Daniel Yuan
Mar 21, 20255 min read
The Oncology Pipeline Investment Dilemma: What’s Biopharma’s Next Strategic Move?
Should biopharma continue prioritizing IOs, or shift to TTs and next-generation approaches like ADCs, radiopharma, and cytokine-based IO?
Fraol Galan
Mar 17, 20253 min read
bottom of page